HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kerr, D. E. Articles by Wellnitz, O. Search for Related Content PubMed PubMed Citation Articles by Kerr, D. E. Articles by Wellnitz, O.

Mammary expression of new genes to combat mastitis

Department of Animal Science, University of Vermont, Burlington 05405

Corresponding author: D. E. Kerr; e-mail: dkerr{at}uvm.edu.

Continual advances in the ability to produce transgenic animals make it likely that such animals will become important components of animal agriculture. The full benefit of the technology, and justification of its initial cost outlay, will be dependent on the establishment within these animals of new traits not easily achievable by other means. Potential applications include enhanced nutrient digestibility with reduced fecal losses, significantly altered milk composition with superior nutritional properties, and enhanced disease resistance. Our goal is to enhance mastitis resistance of dairy cows by enabling the cells of the mammary gland to secrete additional antibacterial proteins. Proof of concept has been obtained through experimentation with a transgenic mouse model. Three lines of mice were developed that produce varying levels of lysostaphin in their milk. This protein has potent anti-staphylococcal activity and its secretion into milk confers substantial resistance to infection caused by intramammary challenge with Staphylococcus aureus, a major mastitis pathogen. Additional antibacterial proteins are being sought that will complement lysostaphin. A potential benefit of transgenic application of antibacterial proteins is the concomitant sparing in the agricultural use of antibiotics currently used as human therapeutics. Antibacterial proteins, such as lysostaphin, are not typically used as injectable or oral therapeutics because of immune-mediated or digestive destruction of their activity. In contrast, the immune system of transgenic animals will not consider the transgenic protein as being foreign. In addition we are exploring the potential of involution or mastitis responsive promoter elements for use in subsequent transgenic experiments designed to restrict lysostaphin production to these important time points. It is anticipated that genomics will play a role in unveiling candidate genes whose promoter elements will enable desired temporal expression patterns. The transgenic approach to insertion of new genetic material into agriculturally important animals is feasible but requires extensive prior evaluation of the transgene and transgene product in model systems.

Key Words: Mastitis • Staphylococcus aureus • Transgenic • Mice

This article has been cited by other articles:

				D. L. Van Hekken, R. J. Wall, G. A. Somkuti, M. A. Powell, M. H. Tunick, and P. M. Tomasula Fate of lysostaphin in milk from individual cows through pasteurization and cheesemaking J Dairy Sci, February 1, 2009; 92(2): 444 - 457. [Abstract] [Full Text] [PDF]

				J. Conington, G. Cao, A. Stott, and L. Bunger Breeding for resistance to mastitis in United Kingdom sheep, a review and economic appraisal Vet Rec., March 22, 2008; 162(12): 369 - 376. [Abstract] [Full Text] [PDF]

				D. M. Donovan, J. Foster-Frey, S. Dong, G. M. Rousseau, S. Moineau, and D. G. Pritchard The Cell Lysis Activity of the Streptococcus agalactiae Bacteriophage B30 Endolysin Relies on the Cysteine, Histidine-Dependent Amidohydrolase/Peptidase Domain. Appl. Envir. Microbiol., July 1, 2006; 72(7): 5108 - 5112. [Abstract] [Full Text] [PDF]